Cochlear Stock Rating Reaffirmed by Credit Suisse (COH)
Cochlear (ASX:COH)‘s stock had its “underperform” rating reiterated by analysts at Credit Suisse in a research report issued to clients and investors on Thursday, AR Network reports.
Shares of Cochlear (ASX:COH) traded down 1.00% during mid-day trading on Thursday, hitting A$61.160. 162,180 shares of the company’s stock traded hands. Cochlear has a 1-year low of A$52.710 and a 1-year high of A$82.870. The stock’s 50-day moving average is A$58.76 and its 200-day moving average is A$62.46. The company has a market cap of A$3.481 billion and a price-to-earnings ratio of 26.58.
COH has been the subject of a number of other recent research reports. Analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Cochlear (ASX:COH) in a research note to investors on Monday. Separately, analysts at CIMB reiterated an “underperform” rating on shares of Cochlear (ASX:COH) in a research note to investors on Sunday, August 25th. Finally, analysts at CIMB reiterated an “underperform” rating on shares of Cochlear (ASX:COH) in a research note to investors on Friday, August 16th. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company’s stock. Cochlear currently has an average rating of “Hold” and a consensus price target of A$70.54 ($66.55).
Cochlear Limited (ASX:COH) is an Australia-based company, which operates in the implantable hearing device industry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.